['Sequential treatments using various targeted-therapies have been recommended for metastatic renal cell carcinoma. However, regimen selection remains difficult when adapting to various clinical situations.', 'From 2006 to 2012, 29 patients who received sequential targeted-therapy at our hospital were included for analysis of the treatment regimens and outcome.', 'Patients who used sunitinib as first-line and axitinib as second-line treatment experienced a similar second-line treatment duration, as those used the same first-line and everolimus as the second-line regimen. The first-line sunitinib treatment duration was longer in the axitinib group.'] Do first-line treatment result influence second-line regimen selection in targeted therapy for metastatic renal cell carcinoma?